Regeneron's five-year Phase 3 study shows durable survival benefit of Libtayo in PD-L1-high NSCLC

WASHINGTON (dpa-AFX) – Regeneron Pharmaceuticals Inc. (REGN) announced that five-year results from the Phase 3 EMPOWER-Lung 1 trial demonstrated durable survival benefit and impressive efficacy of first-line Libtayo monotherapy compared with chemotherapy in patients with advanced PD-L1-high non-small cell lung cancer, highlighting a direct link between survival benefits and PD-L1 expression levels.

The study evaluated Libtayo (cemiplimab) as monotherapy compared with chemotherapy as first-line treatment for adults with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression of at least 50% and no EGFR, ALK or ROS1 aberrations.

Recent data from the IASLC 2024 World Conference on Lung Cancer (WCLC) showed that Libtayo monotherapy almost doubled median overall survival compared with chemotherapy and reduced the risk of death and disease progression by 41% and 50%, respectively.

The WCLC presentation will also examine overall survival, progression-free survival and response rate data in patients who received chemotherapy in addition to Libtayo after disease progression.

The exploratory subgroup analysis of EMPOWER-Lung 1 also showed direct correlations between survival and disease progression benefits and PD-L1 expression level in Libtayo patients, supporting the previously observed direct correlation between tumor response and PD-L1 expression level.

For more health news like this, visit rttnews.com.

Copyright(c) 2024 RTTNews.com. All rights reserved

Copyright RTT News/dpa-AFX